Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00778193
Other study ID # Healing Study
Secondary ID GA319181
Status Completed
Phase Phase 4
First received July 24, 2008
Last updated October 22, 2008
Start date October 2007
Est. completion date March 2008

Study information

Verified date October 2008
Source Research Associates of New York, LLP
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Gastroduodenal ulcers are extremely common in the community today. Though much has been written and observed concerning how ulcers form, not much has been described in the human model concerning how these ulcers heal. As numerous patients already suffer from gastrointestinal ulcers, further clarification of ulcer healing would be valuable in the treatment and management of these patients. The goal of this study is to investigate the effects of naproxen, aspirin, celecoxib, and clopidogrel on biopsy-induced gastroduodenal lesions in order to elucidate the mechanisms of ulcer healing. This single site, single-blind, randomized, placebo-controlled, one-week prospective study will examine ulcer healing through endoscopic, immunohistologic, and molecular PCR modalities.


Description:

In order to assess the extent of healing of the biopsy sites, a 12-point scale was developed and validated.

After all of the procedures were complete, this scale was used to measure the effects of the study drugs on the healing of the biopsy-induced ulcers.


Recruitment information / eligibility

Status Completed
Enrollment 125
Est. completion date March 2008
Est. primary completion date March 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Signed informed consent

- Age 18-75

- Use of appropriate form of birth control for women of childbearing potential.

Exclusion Criteria:

- H pylori infection

- Use of NSAIDs within 2 weeks prior to start of enrollment

- Use of antacids or H-2 blockers within 2 weeks of enrollment

- Use of PPIs within 30 days of enrollment

- Corticosteroid use within 60 days of enrollment

- History of a previous ulcer

- Diagnosis of a bleeding diathesis or use of warfarin within 60 days of enrollment

- Use of cigarettes within 6 months of enrollment

- Consumption of >3 alcoholic beverages per day

- Hypersensitivity or allergy to NSAIDs, clopidogrel, or corn starch, or any contraindications to ingesting those substances

- The presence of an ulcer at a baseline endoscopy

- Endoscopically severe gastritis or duodenitis baseline endoscopy

- Moderate or severe inflammation located within the duodenal bulb or within 2cm of the pyloric channel at a baseline endoscopy

- Any gastroduodenal tumor.

Study Design

N/A


Related Conditions & MeSH terms


Intervention

Drug:
Naproxen
1 tablet 500mg BID for 8 days
Aspirin
1 tablet 81mg QD for 8 days
Celecoxib
1 capsule 200mg QD for 8 days
Clopidogrel
Day 0: 4 tablets QD for 1 day; Days 1-7: 1 tablet QD for 7 days
Placebo
1 capsule BID for 8 days

Locations

Country Name City State
United States Research Associates of New York New York New York

Sponsors (1)

Lead Sponsor Collaborator
Research Associates of New York, LLP

Country where clinical trial is conducted

United States, 

References & Publications (1)

Desai JC, Sanyal SM, Goo T, Benson AA, Bodian CA, Miller KM, Cohen LB, Aisenberg J. Primary prevention of adverse gastroduodenal effects from short-term use of non-steroidal anti-inflammatory drugs by omeprazole 20 mg in healthy subjects: a randomized, double-blind, placebo-controlled study. Dig Dis Sci. 2008 Aug;53(8):2059-65. doi: 10.1007/s10620-007-0127-4. Epub 2008 Jan 26. — View Citation

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04123899 - BE Study of Gaster®D Tab 20mg (Manufacturer Changed) N/A
Recruiting NCT06393907 - Hemostatic Forceps vs. Bipolar Electrocautery Probes for High-Risk Bleeding Gastroduodenal Ulcers N/A
Completed NCT02175186 - Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Phase 4
Completed NCT03163680 - Efficacy of Low Dose of Proton Pump Inhibitor in Treatment Bleeding Ulcers
Not yet recruiting NCT02882477 - Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy Phase 2/Phase 3
Withdrawn NCT02724150 - Comparison of Low Against High Regimen of Proton Pump Inhibitors for Treatment of Acute Peptic Ulcer Bleeding Phase 4